Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pauwels

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Tobacco Prevention & Cessation|July 21, 2022
Review of industry reports on EU priority tobacco additives part A: Main outcomes and conclusionsAnne Havermans, Nadja Mallock, Efthimios Zervas, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 StudiesSebastiaan Ten Bokkel Huinink, Doranne Thomassen, Ewout W Steyerberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 2, 2021
Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 StudiesRenske W M Pauwels, C Janneke van der Woude, Daan Nieboer, et al.
Journal of Crohn'S & Colitis|June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.
Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The American Journal of Gastroenterology|August 16, 2017
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French AdolescentsSilvia Ghione, Hélène Sarter, Mathurin Fumery, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Tobacco Prevention & Cessation|July 21, 2022
Review of industry reports on EU priority tobacco additives part A: Main outcomes and conclusionsAnne Havermans, Nadja Mallock, Efthimios Zervas, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 StudiesSebastiaan Ten Bokkel Huinink, Doranne Thomassen, Ewout W Steyerberg, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 2, 2021
Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 StudiesRenske W M Pauwels, C Janneke van der Woude, Daan Nieboer, et al.
Journal of Crohn'S & Colitis|June 13, 2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI TrialFenna M Jansen, Reinier C A van Linschoten, Wietske Kievit, et al.
Digestive Diseases and Sciences|April 9, 2024
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI TrialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The Lancet. Gastroenterology & Hepatology|February 3, 2023
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trialReinier C A van Linschoten, Fenna M Jansen, Renske W M Pauwels, et al.
The American Journal of Gastroenterology|August 16, 2017
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French AdolescentsSilvia Ghione, Hélène Sarter, Mathurin Fumery, et al.
Pageof 9